Asarfi Hospital Ltd

Meeting Details

• Date: 25 August 2026.
• Time: 11:00 A.M.
• Venue: Registered Office, Asarfi Hospital Limited, Baramuri Bishunpur Polytechnic, Dhanbad, Jharkhand 828130.

Key Agenda Items

• To consider and approve Directors’ Report for the financial year ended 31 March 2026.
• Re-appointment of director retiring by rotation: Mr. Gopal Singh (DIN: 01608342) offered for re-appointment.
• Fix date, time and venue of the 21st AGM: 18 September 2026 at 12:00 Noon.
• Approve Book Closure/Record Date for AGM: 5 September 2026 to 18 September 2026.
• Appoint Cost Auditor for FY 2026-27: M/s Ashutosh Kumar Sinha & Co.
• Approve the AGM Notice along with Directors’ Report and documents.
• Discuss migration from BSE SME to BSE Main Board and NSE listing.

Publication of results

• Unaudited standalone and consolidated results for the quarter ended June 30, 2026 disclosed.
• Audit Committee approved the results; Board approval dated August 7, 2026.
• Newspaper advertisements published August 8, 2026 in The Times of India (Ranchi), Hindustan and Dainik Jagran.

Key metrics and outlook

• Revenue from operations and total income disclosed for both standalone and consolidated.
• FY27 revenue guidance: Rs 4,734 lakhs with EBITDA margin of 20% and PAT margin of 9%.
• Earnings per share information disclosed in the results.

Regulatory filing

• Results filed with stock exchanges as per regulatory requirements.

Financial highlights

• Standalone Q1 FY27 revenue ₹4,734.47 Lakhs; YoY growth 33%; EBITDA margin 20%; PAT margin 9%.
• Consolidated Q1 FY27 revenue ₹4,753.41 Lakhs; PAT ₹426.72 Lakhs; Basic EPS ₹2.17.
• IPD revenue up 31% YoY; OPD up 44% YoY; ARPOB ₹23,498 and ₹31,892 for Super-Specialty and Cancer.
• Unaudited results approved by Board on 07-Aug-2026; Audit Committee recommendations reported.

Financial results approved

• Board approved unaudited standalone and consolidated results for the quarter ended 30 June 2026.

Audit reports

• Limited Review Reports on standalone and consolidated results issued by the statutory auditors.

Key financial metrics

• Standalone quarterly revenue 4,793.73 Lakhs; PAT 426.84 Lakhs; EPS 2.17.
• Consolidated quarterly revenue 4,810.00 Lakhs; PAT 426.72 Lakhs; EPS 2.17.

Financial statements filed

• Balance sheets and cash flow statements for the quarter filed (standalone and consolidated).

Board meeting details

• Board meeting held on 7 August 2026.

Webinar highlights

• Consistent YoY revenue and PAT growth; target revenue of ₹400 crore by FY2028.
• Oncology expansion with a dedicated cancer hospital; growth drivers: cardiology, oncology, and neurosurgery.
• Bid for 100-seat Medical College under PPP; nursing and paramedical colleges being established.
• Proposed Bone Marrow Transplant facility; focus on occupancy targets and doctor retention strategy.
• Initiated migration prep to the Main Board, subject to eligibility criteria and regulatory approvals.
• Evaluating acquisition of a 70-bed hospital to strengthen regional presence.
• No Unpublished Price Sensitive Information (UPSI) discussed during the webinar.

Meeting Details

• Date and time: July 24, 2026, 4:30–5:30 IST.
• Format: Virtual group meeting.
• Organizer: Hem Securities Ltd.

Participants

• Key company participant: Company Secretary & Compliance Officer.

Purpose

• Purpose: discuss the Q4 and annual results presentation for quarter ended March 31, 2026.

Additional Notes

• Investor presentation for the period is available on the company and BSE websites.
• The presentation will be used during the meeting.

Asarfi Hospital Limited: Trading Window closed for Designated Persons from July 01, 2026; shall reopen 48 hours after the declaration of the Unaudited Financial Results for the quarter ended June 30, 2026.

FY26 results

• Consolidated revenue rose 42% year-on-year to ₹173.5 crore.
• EBITDA increased 42% to ₹35.3 crore; margin was 20%.
• EBIT rose 44% to ₹26.4 crore.
• PAT grew 58% to ₹16.7 crore; PAT margin was 10%.

Operations

• IPD revenue increased 46% and OPD revenue increased 34% in FY26.
• In-patient volume crossed 16,000; out-patient volume reached about 1.38 lakh.
• Super specialty ARPOB improved to ₹23,000.
• Total surgeries increased 26% year-on-year to over 6,300 procedures.
• Cancer hospital occupancy improved to 42% in FY26.
• Q4 revenue was ₹45.2 crore, up 29% year-on-year.
• Q4 EBITDA was ₹7.7 crore with 17% margin.
• Q4 PAT rose 9% year-on-year to ₹3.9 crore.

Guidance and capex

• Vision 2028 targets 500-plus beds, about ₹400 crore revenue, and 23%-25% EBITDA margin.
• FY27 EBITDA margin target is at least 22%, with 23%-25% longer term.
• FY27 revenue target is ₹260 crore, including organic and inorganic growth.
• Cancer hospital beds will rise from 65 to 150 with ₹2-3 crore capex.
• Management expects no major external funding for the bed expansion.
• Bone marrow transplant approval may take another four to five months.
• Healthcare Management Research Institute capex is estimated at ₹8-10 crore.
• Total current-year capex is expected to stay below ₹15 crore.
• Cash balance was stated at ₹8-10 crore.

Q&A Highlights

• Analysts asked about Ayushman Bharat exposure; management said it applies only to the cancer hospital and contributes about 15% of cancer revenue.
• Analysts asked about delayed bone marrow launch; management said Jharkhand approval is pending and doctors are already hired.
• Analysts asked about the merger of another hospital; management said shareholder inheritance issues are delaying completion.
• Analysts asked about future expansion; management said more hospitals under management are being planned, but the operating model is still being finalized.
• Analysts asked about cancer patient decline in Q4; management said government approval changes caused administrative delays.
• Analysts asked about cancer revenue contribution; management said cancer contributes 10%-12% of company revenue.
• Analysts asked about receivables; management said debtor aging is around six to seven months.
• Analysts asked about debt for growth; management said growth is currently planned through internal accruals, though debt remains possible.
• Analysts asked about the ₹260 crore target; management said it is supported by existing hospitals, added cardiac beds, and cancer expansion.
• Analysts asked about the 1,000-bed target; management said it still holds before FY30.